CO4600638A1 - Virosomas cationicos como sistema de transferencia para material genetico - Google Patents

Virosomas cationicos como sistema de transferencia para material genetico

Info

Publication number
CO4600638A1
CO4600638A1 CO97024481A CO97024481A CO4600638A1 CO 4600638 A1 CO4600638 A1 CO 4600638A1 CO 97024481 A CO97024481 A CO 97024481A CO 97024481 A CO97024481 A CO 97024481A CO 4600638 A1 CO4600638 A1 CO 4600638A1
Authority
CO
Colombia
Prior art keywords
fusion peptide
lipid bilayer
viral fusion
cationic
membrane
Prior art date
Application number
CO97024481A
Other languages
English (en)
Spanish (es)
Inventor
Peter Klein
Reinhard Gluck
Ernst Rudolf Walti
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of CO4600638A1 publication Critical patent/CO4600638A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CO97024481A 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico CO4600638A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08

Publications (1)

Publication Number Publication Date
CO4600638A1 true CO4600638A1 (es) 1998-05-08

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97024481A CO4600638A1 (es) 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico

Country Status (28)

Country Link
US (1) US6210708B1 (enExample)
EP (1) EP0902682A2 (enExample)
JP (1) JP2000509404A (enExample)
KR (1) KR100536983B1 (enExample)
CN (1) CN1271992C (enExample)
AR (1) AR007054A1 (enExample)
AU (1) AU710170B2 (enExample)
BG (1) BG102880A (enExample)
BR (1) BR9709224A (enExample)
CA (1) CA2253561A1 (enExample)
CO (1) CO4600638A1 (enExample)
CZ (1) CZ299809B6 (enExample)
EA (1) EA003130B1 (enExample)
GT (1) GT199700058A (enExample)
HR (1) HRP970234B1 (enExample)
HU (1) HUP9901790A3 (enExample)
ID (1) ID17934A (enExample)
NO (1) NO327726B1 (enExample)
NZ (1) NZ332666A (enExample)
OA (1) OA10916A (enExample)
PA (1) PA8429201A1 (enExample)
PE (1) PE65198A1 (enExample)
PL (1) PL199201B1 (enExample)
SK (1) SK152698A3 (enExample)
SV (1) SV1997000032A (enExample)
TN (1) TNSN97080A1 (enExample)
WO (1) WO1997041834A1 (enExample)
ZA (1) ZA973885B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
EP1011735A1 (en) * 1997-09-08 2000-06-28 Promega Corporation METHOD OF $i(IN VIVO) TRANSFORMATION UTILIZING LIPID VEHICLES
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
ES2215073T3 (es) * 1999-10-08 2004-10-01 Nika Health Products Limited Virosomas de dosper cationicos.
JP4112860B2 (ja) * 1999-12-17 2008-07-02 ショット アクチエンゲゼルシャフト 乗員の拘束システムの誘導作動式点火カプセルおよび点火カプセル用のテスト回路
WO2001052901A1 (en) * 2000-01-21 2001-07-26 Hisamitsu Pharmaceutical Co., Inc. Drugs for gene therapy
EP1409653A4 (en) * 2001-07-23 2006-05-03 Onyx Pharma Inc IN HUMAN TARGET CANCELLS SELECTIVELY REPLICATING VIRUS MUTANTS
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
CN100488491C (zh) * 2002-11-21 2009-05-20 派维翁生物技术有限公司 高效融合小泡,其制备方法和含有该小泡的药物组合物
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
CA2663034C (en) 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
WO2013050048A2 (en) * 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
WO2018060213A1 (en) 2016-09-27 2018-04-05 Camurus Ab Formulations containing a somatostatin receptor agonist
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
JPH06500128A (ja) * 1991-05-08 1994-01-06 シュバイツ・ゼルム―・ウント・インプフィンスティテュート・ベルン 免疫刺激及び免疫増強性再構成インフルエンザウイロソーム及びそれを含有するワクチン
AU3614493A (en) 1992-02-04 1993-09-01 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
JPH10505320A (ja) * 1994-05-31 1998-05-26 イネックス ファーマシューティカルズ コーポレイション 治療剤のビロゾーム媒介細胞内輸送
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
CN1271992C (zh) 2006-08-30
NO985137L (no) 1999-01-04
HUP9901790A2 (hu) 1999-08-30
SV1997000032A (es) 1998-03-27
BR9709224A (pt) 1999-08-10
PL329853A1 (en) 1999-04-12
OA10916A (en) 2003-02-21
KR100536983B1 (ko) 2006-06-29
JP2000509404A (ja) 2000-07-25
TNSN97080A1 (fr) 2005-03-15
NO327726B1 (no) 2009-09-14
ID17934A (id) 1998-02-12
PE65198A1 (es) 1998-10-16
AR007054A1 (es) 1999-10-13
HRP970234A2 (en) 1998-06-30
EA199800992A1 (ru) 1999-06-24
BG102880A (en) 1999-05-31
ZA973885B (en) 1998-11-06
HRP970234B1 (en) 2002-04-30
NZ332666A (en) 2000-05-26
CA2253561A1 (en) 1997-11-13
US6210708B1 (en) 2001-04-03
CZ361498A3 (cs) 1999-03-17
EP0902682A2 (en) 1999-03-24
EA003130B1 (ru) 2003-02-27
KR20000010780A (ko) 2000-02-25
GT199700058A (es) 1998-10-29
CN1225007A (zh) 1999-08-04
HUP9901790A3 (en) 2010-11-29
SK152698A3 (en) 1999-05-07
WO1997041834A1 (en) 1997-11-13
AU2776697A (en) 1997-11-26
PA8429201A1 (es) 2000-05-24
CZ299809B6 (cs) 2008-12-03
PL199201B1 (pl) 2008-08-29
NO985137D0 (no) 1998-11-04
AU710170B2 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
CO4600638A1 (es) Virosomas cationicos como sistema de transferencia para material genetico
Helenius et al. On the entry of Semliki forest virus into BHK-21 cells
Ives et al. Preparation of functional smooth muscle cells from the rabbit aorta.
Volsky et al. An efficient method for reassembly of fusogenic Sendai virus envelopes after solubilization of intact virions with Triton X-100
Metsikkö et al. Reconstitution of the fusogenic activity of vesicular stomatitis virus.
Benaroch et al. HIV-1 assembly in macrophages
Mayer et al. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential
Stegmann et al. Functional reconstitution of influenza virus envelopes.
van Meer et al. The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral cell surface domains of MDCK cells.
Tsurudome et al. Lipid interactions of the hemagglutinin HA2 NH2-terminal segment during influenza virus-induced membrane fusion.
Greber et al. Mechanisms of virus uncoating
Glick et al. Protein import into mitochondria: two systems acting in tandem?
Hosaka et al. Electron microscopic study of cell fusion by HVJ virions
Bron et al. [23] Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes)
Hsu et al. Fusion of Sendai virus with liposomes: Dependence on the viral fusion protein (F) and the lipid composition of liposomes
Dowdall et al. Recent studies on the comparative biochemistry of the cholinergic neuron
Roessner et al. Injection of DNA into liposomes by bacteriophage lambda.
Tilly et al. Increased aminophospholipid translocase activity in human platelets during secretion
Rizzo et al. Liposome-mediated transfer of simian virus 40 DNA and minichromosome into mammalian cells
Kosower et al. Membrane mobility agents. IV. The mechanism of particle-cell and cell-cell fusion
Semin et al. Calorimetric studies of cytochrome oxidase-phospholipid interactions
WO2024093036A1 (en) A method to increase the loading of specific nucleic acid molecules in engineered cell exosomes and its application
Gibbons et al. Purification and crystallization reveal two types of interactions of the fusion protein homotrimer of Semliki Forest virus
Kogure et al. Effect of dicetylphosphate or stearic acid on spontaneous transfer of protein from influenza virus-infected cells to dimyristoylphosphatidylcholine liposomes
AU2002232379B2 (en) Oligonucleotide - facilitated coalescence